SIGLEC1 and neoplasm: They conducted experiments in vitro and in vivo, and found that Naringin can induce lymph node macrophages to activate into CD169 positive phenotype, fully upregulate the expression of CD169 in macrophages, thereby enhancing anti-tumor immunity (Fujiwara et al., 2018).